$12,427.44 consulting Payment -- Roche/Genentech to Dr. Elizabeth Roberts
Hematologist Elizabeth Roberts Receives $12,427 Consulting Fee from Roche/Genentech for Entresto
This page provides a detailed analysis of a $12,427.44 consulting payment from Roche/Genentech to Dr. Elizabeth Roberts. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $12,427.44 |
| Payment Type | consulting |
| Payment Nature | Consulting Fee |
| Pharmaceutical Company | Roche/Genentech |
| Physician | Dr. Elizabeth Roberts |
| NPI Number | 1816845605 |
| Physician Specialty | Hematology |
| Location | City, LA |
| Date of Payment | 2026-03-26 |
| Related Drug/Device | Entresto |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Roche/Genentech made a $12.4K consulting payment to Elizabeth Roberts, a Hematology specialist in City, LA. The payment was associated with Entresto. Elizabeth Roberts received a $12,427.44 consulting fee from Roche/Genentech on March 26, 2026. The payment was for consulting services related to the drug Entresto. This payment falls under the 'consulting fee' category, indicating a service-based arrangement.
Patient Guidance: What This Payment Means for You
This information details a payment made to a healthcare professional for consulting services. It is important to understand the nature of such payments to ensure transparency in healthcare. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Consulting fees for specialists like hematologists can vary widely based on expertise, project scope, and the pharmaceutical company's needs; this amount should be evaluated against industry benchmarks for similar consulting engagements.
Regulatory Context: Sunshine Act Requirements
Payments to physicians from pharmaceutical companies are subject to disclosure under the Sunshine Act (part of the Affordable Care Act), requiring reporting of transfers of value.
Related Topics
This payment is related to the following healthcare transparency topics:
- consulting-fee
- roche-genentech
- elizabeth-roberts
- entresto
- hematology
- payment-analysis
Understanding consulting Payments
Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.
Frequently Asked Questions About This Payment
What was this $12.4K payment for?
This was a consulting payment of $12.4K from Roche/Genentech to Elizabeth Roberts, categorized as "Consulting Fee". It was associated with Entresto. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Elizabeth Roberts accept pharmaceutical money?
Yes, Elizabeth Roberts received this $12.4K payment from Roche/Genentech. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Elizabeth Roberts's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this consulting payment?
A consulting payment of $12.4K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Hematology?
To compare this payment against Hematology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Hematology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Elizabeth Roberts's relationship with Roche/Genentech?
The payment amount is substantial, suggesting significant consulting engagement. This $12.4K consulting payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Hematology?
The specific drug, Entresto, is mentioned, providing clarity on the focus of the consulting.
What should patients do after learning about this payment?
This information details a payment made to a healthcare professional for consulting services. It is important to understand the nature of such payments to ensure transparency in healthcare.
What else should I know about this consulting payment?
The payment date is in the future (2026), which is unusual for reported data and may indicate a future agreement.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.